PDO MAX INC, a medical device provider for medical aesthetic needs in the United States and Canadian markets, has received 510(k) approval from the US Food and Drug Administration (FDA) for its brand of PDO (polydioxanone) absorbable threads in cannula, it was reported on Friday.
PDO threads are utilised in aesthetic medicine and are a sterile, biodegradable, monofilament synthetic composed polymer. The approval is for both the PDO threads and cannula integrated into one device, unlike many of the other providers in the market.
Juliana Ucchino, vice president of Operations for PDO Max Inc, said, 'We are dedicated to bringing our aesthetic medical professionals, true peace of mind with our FDA cleared PDO threads. PDO MAX threads, used alone, or in addition to the provider's preferred injectable product, greatly add to the ability of our medical professionals to deliver nonsurgical, minimally invasive total facial aesthetics solutions.'
Ascletis selects once-monthly SQ GLP-1R/GIPR dual peptide agonist, ASC35, for clinical development
Celltrion's biosimilar EYDENZELT (aflibercept-boav) approved by US FDA
Rigel Pharmaceuticals begins dose expansion phase of R289 study in lower-risk MDS
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Oxford Biomedica expands US operations with acquisition of viral vector facility in North Carolina
DarioHealth and OneStep partner to integrate fall risk technology into digital health platform